January 21, 2022
Authors Natansh D Modi1, Nicolas O Danell1, Riley NA Perry1, Ahmad Y Abuhelwa1, Akash Rathod1, Sarah Badaoui1, Ross A McKinnon1, Mark Haseloff1, Adel Shahnam2, Sandra M Swain3, Manfred Welslau4, Michael J Sorich1, and Ashley M Hopkins1
Affiliations 1. College of Medicine and Public Health, Flinders University, South Australia, Australia. 2. Crown Princess Mary Cancer Centre, Westmead Hospital, New South Wales, Australia. 3. University of Georgetown Medical Center, Washington DC, USA. 4. Onkologie Aschaffenburg, Aschaffenburg, Germany
Presentation type Oral
Presenters Natansh D Modi
Background The prognostic value of patient-reported outcomes (PROs) has been minimally explored in advanced breast cancer, and their comparative prognostic performance against Eastern Cooperative Oncology Group performance status (ECOG PS) is largely unknown. Methods This study pooled individual participant data from clinical trials CLEOPATRA, EMILIA, and MARIANNE. Pre-treatment PRO associations with overall survival (OS), progression-free […]
